DRG Market Assessment reports

Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…

Over the last 15 years, we have witnessed a notable shift in oncology drug development activity. Since the U.S. approval of Roche/Genentech’s Herceptin (trastuzumab) in 1998, pharmaceutical…

Is There a Disconnect Between Physician and Payer Perceptions of Therapies Across Key Indications? The treatment of both solid and hematological cancers is associated with a wide range of…

How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational status of their…

Cancer treatment is rapidly evolving and demand for more than modest incremental efficacy gains in highly competitive markets is growing. Given the complexity of the multiple pathways and aberrant…

The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…

Impact of Specialty Pharmacy, Site of Care, and Practice Ownership on Physician Behavior Chemotherapy dominates treatment of both ovarian cancer and endometrial cancer, although Avastin, a…

U.S. Payer and Prescriber Perspectives on Clinical Pathways, Bundled Payments, and Accountable Care Organizations As the U.S. healthcare market faces an avalanche of expensive specialty drugs…

A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…

Pancreatic cancer (PaC) is one of the most aggressive and highly lethal solid malignancies, with a 5-year survival of only 5%. Treatment of PaC is largely dependent on tumor size and location…

A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to…

Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…